Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Research & Development (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Research & Development for 8 consecutive years, with $19.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 32.58% to $19.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $91.0 million through Dec 2025, up 78.25% year-over-year, with the annual reading at $91.0 million for FY2025, 78.25% up from the prior year.
  • Research & Development for Q4 2025 was $19.0 million at Whitehawk Therapeutics, up from $14.3 million in the prior quarter.
  • The five-year high for Research & Development was $48.8 million in Q2 2025, with the low at $3.0 million in Q2 2021.
  • Average Research & Development over 5 years is $12.2 million, with a median of $10.5 million recorded in 2023.
  • Peak annual rise in Research & Development hit 272.79% in 2025, while the deepest fall reached 35.35% in 2025.
  • Over 5 years, Research & Development stood at $7.2 million in 2021, then rose by 29.65% to $9.4 million in 2022, then skyrocketed by 36.26% to $12.8 million in 2023, then grew by 12.37% to $14.3 million in 2024, then surged by 32.58% to $19.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $19.0 million, $14.3 million, and $48.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.